| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9343(97)89442-9 |
| P698 | PubMed publication ID | 9845493 |
| P50 | author | Michael Saag | Q6834090 |
| P2860 | cites work | Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation | Q44352799 |
| A Pilot Study to Evaluate the Development of Resistance to Nevirapine in Asymptomatic Human Immunodeficiency Virus-Infected Patients with CD4 Cell Counts of >500/mm3 : AIDS Clinical Trials Group Protocol 208 | Q44767336 | ||
| Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group | Q45771512 | ||
| High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection | Q45789390 | ||
| Is antiretroviral treatment after percutaneous HIV exposure justified? | Q70705697 | ||
| A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection | Q71523437 | ||
| Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party | Q71523552 | ||
| Safety and activity of saquinavir in HIV infection | Q72152643 | ||
| Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group | Q72547970 | ||
| Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease | Q27675079 | ||
| Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases | Q27730298 | ||
| Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor | Q28323582 | ||
| Rational design of peptide-based HIV proteinase inhibitors | Q28330897 | ||
| Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents | Q28378547 | ||
| L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase | Q28378789 | ||
| HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time | Q29547822 | ||
| Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection | Q29547852 | ||
| Viral dynamics in human immunodeficiency virus type 1 infection | Q29547908 | ||
| HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy | Q29616404 | ||
| Prognosis in HIV-1 infection predicted by the quantity of virus in plasma | Q29619980 | ||
| In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors | Q29620622 | ||
| Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects | Q35232021 | ||
| Viral dynamics of HIV: implications for drug development and therapeutic strategies | Q40983001 | ||
| Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication | Q41981808 | ||
| A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group | Q42274436 | ||
| A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group | Q42278211 | ||
| Ordered accumulation of mutations in HIV protease confers resistance to ritonavir | Q42555782 | ||
| P433 | issue | 5B | |
| P304 | page(s) | 25-31 | |
| P577 | publication date | 1997-05-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | Candidate antiretroviral agents for use in postexposure prophylaxis | |
| P478 | volume | 102 |
Search more.